PRTA - Prothena GAAP EPS of -$0.88 misses by $0.31
- Prothena press release ( NASDAQ: PRTA ): Q2 GAAP EPS of -$0.88 misses by $0.31 .
- Collaboration revenue of $1.31M.
- As of June 30, 2022, Prothena had $510.1 million in cash, cash equivalents and restricted cash, and no debt.
- Outlook: The company continues to expect the full year 2022 net cash used in operating and investing activities to be $120 to $132 million, which includes an expected $40 million clinical milestone payment from Novo Nordisk and expects to end the year with approximately $454 million in cash, cash equivalents and restricted cash (midpoint).
- Net loss is estimated to be between $154 to $170 million, which includes an estimated $32 million of non-cash share-based compensation expense.
For further details see:
Prothena GAAP EPS of -$0.88 misses by $0.31